The estimated Net Worth of Robert C. Fletcher is at least 808 千$ dollars as of 7 January 2020. Mr. Fletcher owns over 1,615 units of Idera Pharmaceuticals stock worth over 7,089$ and over the last 10 years he sold IDRA stock worth over 2,875$. In addition, he makes 798,233$ as Senior Vice President - Business Development and Strategic Planning at Idera Pharmaceuticals.
Robert has made over 1 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,615 units of IDRA stock worth 2,875$ on 7 January 2020.
The largest trade he's ever made was selling 1,615 units of Idera Pharmaceuticals stock on 7 January 2020 worth over 2,875$. On average, Robert trades about 147 units every 0 days since 2015. As of 7 January 2020 he still owns at least 16,485 units of Idera Pharmaceuticals stock.
You can see the complete history of Mr. Fletcher stock trades at the bottom of the page.
Robert Clayton Fletcher is no longer serves as Senior Vice President - Business Development and Strategic Planning of the Company effective 12/31/2020. Mr. Fletcher served in increasingly senior positions at ViroPharma Inc., which was acquired by Shire Plc in January 2014, from April 2001 until January 2014, including as Vice President, Business Development and Project Management from 2005 until January 2014. Mr. Fletcher served as Senior Project Manager at SmithKline Beecham plc, a pharmaceutical company, which was purchased by Glaxo Wellcome plc in December 2000, from 1997 until 2001. Prior to working at SmithKline Beecham, he served as Project Scientist, at Becton, Dickinson and Company, a medical devices company and as Principal Scientist at Intracel Corporation, a biopharmaceutical company. Prior to working at Intracel, he served as Senior Associate Scientist at Centocor Biotech, Inc., a biotechnology company from 1991 until 1993.
As the Senior Vice President - Business Development and Strategic Planning of Idera Pharmaceuticals, the total compensation of Robert Fletcher at Idera Pharmaceuticals is 798,233$. There are 1 executives at Idera Pharmaceuticals getting paid more, with Vincent Milano having the highest compensation of 1,337,220$.
Robert Fletcher is 57, he's been the Senior Vice President - Business Development and Strategic Planning of Idera Pharmaceuticals since 2015. There are 10 older and 6 younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.
Robert's mailing address filed with the SEC is C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON, PA, 19341.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over 20,746,904$ worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth 53,771,070$ . The most active insiders traders include Bros. Advisors Lp14159, L.P...、Bros. Advisors Lp Baker Bro...、Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of 309,429$. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth 6,200$.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: